Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Information, Expiry & Status of FDA Orange Book Patents covering MolPort-000-883-773

Client Email

Product

MolPort-000-883-773
US Patents

PharmaCompass Sponsored Ads

Contact Supplier

Egis Atorvastatin - Dapagliflozin

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

MolPort-000-883-773

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

151 API Suppliers, 71 USDMF, 43 CEP/COS, 22 JDMF, 30 EU WC, 86 KDMF, 26 NDC API, 73 Listed Suppliers, $ API Reference Price

151 API Suppliers
71 USDMF
43 CEP/COS
22 JDMF
30 EU WC
86 KDMF
26 NDC API
73 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

12 Drugs in Development

12 Drugs in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

API Reference Price
API Exports
API Imports
FDF Exports
FDF Imports

INTERMEDIATES

18 API Suppliers

18 API Suppliers

FINISHED DOSAGE FORMULATIONS

1544 FDF Dossiers, 187 FDA Orange Book, 790 Europe, 108 Canada, 85 Australia, 73 South Africa, 301 Listed Dossiers

1544 FDF Dossiers
187 FDA Orange Book
790 Europe
108 Canada
85 Australia
73 South Africa
301 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 20MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 40MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 80MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 10MG BASE, TABLET;ORAL - EQ 20MG BASE, TABLET;ORAL - EQ 40MG BASE, TABLET;ORAL - EQ 80MG BASE, TABLET;ORAL - EQ 10MG BASE;EQ 10MG BASE, TABLET;ORAL - EQ 10MG BASE;EQ 20MG BASE, TABLET;ORAL - EQ 10MG BASE;EQ 40MG BASE, TABLET;ORAL - EQ 10MG BASE;EQ 80MG BASE, TABLET;ORAL - EQ 2.5MG BASE;EQ 10MG BASE, TABLET;ORAL - EQ 2.5MG BASE;EQ 20MG BASE, TABLET;ORAL - EQ 2.5MG BASE;EQ 40MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 10MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 20MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 40MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 80MG BASE

TABLET;ORAL - EQ 10MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 20MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 40MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 80MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 10MG BASE
TABLET;ORAL - EQ 20MG BASE
TABLET;ORAL - EQ 40MG BASE
TABLET;ORAL - EQ 80MG BASE
TABLET;ORAL - EQ 10MG BASE;EQ 10MG BASE
TABLET;ORAL - EQ 10MG BASE;EQ 20MG BASE
TABLET;ORAL - EQ 10MG BASE;EQ 40MG BASE
TABLET;ORAL - EQ 10MG BASE;EQ 80MG BASE
TABLET;ORAL - EQ 2.5MG BASE;EQ 10MG BASE
TABLET;ORAL - EQ 2.5MG BASE;EQ 20MG BASE
TABLET;ORAL - EQ 2.5MG BASE;EQ 40MG BASE
TABLET;ORAL - EQ 5MG BASE;EQ 10MG BASE
TABLET;ORAL - EQ 5MG BASE;EQ 20MG BASE
TABLET;ORAL - EQ 5MG BASE;EQ 40MG BASE
TABLET;ORAL - EQ 5MG BASE;EQ 80MG BASE

RELATED EXCIPIENT COMPANIES

1 Minakem, 1 Evonik, 3 Rochem International Inc, 22 SPI Pharma, 2 Seqens, 14 DKSH, 3 Jai Radhe Sales, 1 Pharm-RX Chemical, 2 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 14 Gangwal Healthcare, 2 Kewpie Corporation, 5 Nanjing Well Pharmaceutical, 3 Pfanstiehl, 1 ACG Worldwide, 7 Actylis, 2 Aeon Procare, 2 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 18 BASF, 1 BioSpectra, 12 Corel Pharma Chem, 7 DFE Pharma, 1 Finar, 10 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 7 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 39 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 17 Microlex e.U, 1 Nanjing Bold Chemical, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 3 Novo Excipients, 3 Pharmatrans-Sanaq, 8 Pluviaendo, 5 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 20 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 3 The Dow Chemical Company, 1 Valens Pharmachem, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

94 Fillers, Diluents & Binders, 56 Coating Systems & Additives, 48 Direct Compression, 34 Disintegrants & Superdisintegrants, 31 Thickeners and Stabilizers, 31 Controlled & Modified Release, 24 Granulation, 23 Solubilizers, 23 Lubricants & Glidants, 22 Taste Masking, 21 Parenteral, 19 Chewable & Orodispersible Aids, 19 Co-Processed Excipients, 18 Film Formers & Plasticizers, 17 Topical, 11 Emulsifying Agents, 9 API Stability Enhancers, 9 Rheology Modifiers, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Coloring Agents, 3 Surfactant & Foaming Agents

94 Fillers, Diluents & Binders
56 Coating Systems & Additives
48 Direct Compression
34 Disintegrants & Superdisintegrants
31 Thickeners and Stabilizers
31 Controlled & Modified Release
24 Granulation
23 Solubilizers
23 Lubricants & Glidants
22 Taste Masking
21 Parenteral
19 Chewable & Orodispersible Aids
19 Co-Processed Excipients
18 Film Formers & Plasticizers
17 Topical
11 Emulsifying Agents
9 API Stability Enhancers
9 Rheology Modifiers
5 Empty Capsules
4 Vegetarian Capsules
4 Coloring Agents
3 Surfactant & Foaming Agents

DIGITAL CONTENT

14 DATA COMPILATION #PharmaFlow, 153 NEWS #PharmaBuzz

14 DATA COMPILATION #PharmaFlow
153 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 662 Finished Drug Prices, 20 Annual Reports

2 US Medicaid Prescriptions
662 Finished Drug Prices
20 Annual Reports

MARKET PLACE

54 APIs, 21 FDF Dossiers, 1 Intermediates

54 APIs
21 FDF Dossiers
1 Intermediates

PATENTS & EXCLUSIVITIES

4 US Patents, 72 Health Canada Patents

4 US Patents
72 Health Canada Patents

REF. STANDARDS & IMPURITIES

6 EDQM, 7 USP, 4 JP, 20 Others

6 EDQM
7 USP
4 JP
20 Others

ANALYTICAL

5 BioAnalytical Methods

5 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 218 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

4 All

01 4CMP DEV LLC

filter Patent Number Reset all filters

4 All

01 111369567

02 211654106

03 111925704

filter API Patent Reset all filters

4 All

01 4Blank

filter FDF Patent Reset all filters

4 All

01 4Y

filter Expiration Date Reset all filters

4 All

01 42037-06-07

DRL Atorvastatin

US Patents
Health Canada Patents

Product Main Page

01

CMP DEV LLC

ATORVASTATIN CALCIUM

AAPS 2024

Not Confirmed

CMP DEV LLC

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-06-07

ATORVASTATIN CALCIUM

US Patent Number : 11654106

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213260

Patent Use Code : U-3612

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-06-07

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

CMP DEV LLC

ATORVASTATIN CALCIUM

AAPS 2024

Not Confirmed

CMP DEV LLC

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-06-07

ATORVASTATIN CALCIUM

US Patent Number : 11654106

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213260

Patent Use Code : U-3613

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-06-07

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

CMP DEV LLC

ATORVASTATIN CALCIUM

AAPS 2024

Not Confirmed

CMP DEV LLC

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-06-07

ATORVASTATIN CALCIUM

US Patent Number : 11925704

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213260

Patent Use Code : U-3853

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-06-07

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

CMP DEV LLC

ATORVASTATIN CALCIUM

AAPS 2024

Not Confirmed

CMP DEV LLC

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-06-07

ATORVASTATIN CALCIUM

US Patent Number : 11369567

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 213260

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-06-07

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?